Kanapathipillai R, Restrepo AM, Fast P, Wood D, Dye C, Kieny MP, Moorthy V.

N Engl J Med. 2014 Oct 7. [Epub ahead of print]

With the Ebola epidemic in West Africa continuing to grow, the World Health Organization (WHO) convened an urgent meeting on September 29 and 30 to assess the efforts under way to evaluate and produce safe and effective Ebola vaccines as soon as possible. The 70 scientists, public health officials, and representatives from industry and regulatory bodies who gathered in Geneva discussed two vaccine candidates at length – cAd3-EBOV (cAd3), from GlaxoSmithKline (GSK) and the U.S. National Institute of Allergy and Infectious Diseases (NIAID), and rVSV?G-EBOV-GP (rVSV), from NewLink Genetics and the Public Health Agency of Canada.Several other vaccine candidates are at earlier, preclinical stages in the development pipeline.